At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
tacrolimus +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis After Allogeneic Non-myeloablative Peripheral Blood Stem Cell Transplantation
In Brief
A Phase 2 clinical trial evaluating tacrolimus, sirolimus, and 2 other interventions for Graft Versus Host Disease and GVHD. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The purpose of this study is to extend the use of Tacrolimus and Sirolimus to determine how effective it is in preventing graft versus host disease (GVHD)in patients that have received non-myeloablative peripheral blood stem cell transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft Versus Host Disease, GVHD
CountriesUnited States
CollaboratorsBrigham and Women's Hospital
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedJan 2006
Primary CompletionJan 2009
Study CompletionJul 2009
TodayJul 2026
First PostedJan 26, 2006
Enrollment StartJan 1, 2006
Primary CompletionJan 1, 2009
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.4 years ago
Interventions
tacrolimusdrug
Given orally just prior to and following stem cell transplant
sirolimusdrug
Given orally just prior to and following stem cell transplant
fludarabinedrug
Given once daily over 30 minutes for 4 days
busulfexdrug
Given intravenously over 3 hours for 4 days